A V D'Amico

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi Combined-modality staging for localized adenocarcinoma of the prostate
    A V D'Amico
    Brigham and Women s Hospital, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Oncology (Williston Park) 15:1049-59; discussion 1060-2, 1064-5, 1069-70,1073-5. 2001
  2. ncbi Real-time magnetic resonance imaging-guided brachytherapy in the treatment of selected patients with clinically localized prostate cancer
    A D'Amico
    Joint Center for Radiation Therapy, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Endourol 14:367-70. 2000
  3. ncbi Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer
    A V D'Amico
    Brigham and Women s Hospital and Dana Farber Cancer Institute, Department of Radiation Therapy, Harvard Medical School, 75 Francis St, L 2 Level, Boston, MA 02115, USA
    JAMA 284:1280-3. 2000
  4. ncbi Utilizing predictions of early prostate-specific antigen failure to optimize patient selection for adjuvant systemic therapy trials
    A V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 18:3240-6. 2000
  5. ncbi Pathologic findings and prostate specific antigen outcome after radical prostatectomy for patients diagnosed on the basis of a single microscopic focus of prostate carcinoma with a gleason score </= 7
    A V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer 89:1810-7. 2000
  6. ncbi Clinical utility of percent-positive prostate biopsies in predicting biochemical outcome after radical prostatectomy or external-beam radiation therapy for patients with clinically localized prostate cancer
    A V D'Amico
    Joint Center for Radiation Therapy, Harvard Medical School, Boston, Massachusetts 02215, USA
    Mol Urol 4:171-5;discussion 177. 2000
  7. ncbi A practical method to achieve prostate gland immobilization and target verification for daily treatment
    A V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02115, USA
    Int J Radiat Oncol Biol Phys 51:1431-6. 2001
  8. ncbi The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external-beam radiation therapy for patients with clinically localized prostate cancer
    A V D'Amico
    Joint Center for Radiation Therapy, Harvard Medical School, Boston, MA, USA
    Int J Radiat Oncol Biol Phys 49:679-84. 2001
  9. ncbi Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer
    A D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital, Boston, Massachusetts 02215, USA
    Urology 58:78-82. 2001
  10. ncbi Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer
    A V D'Amico
    Joint Center for Radiation Therapy, Harvard Medical School, Boston, MA 02215, USA
    J Clin Oncol 18:1164-72. 2000

Collaborators

Detail Information

Publications41

  1. ncbi Combined-modality staging for localized adenocarcinoma of the prostate
    A V D'Amico
    Brigham and Women s Hospital, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Oncology (Williston Park) 15:1049-59; discussion 1060-2, 1064-5, 1069-70,1073-5. 2001
    ....
  2. ncbi Real-time magnetic resonance imaging-guided brachytherapy in the treatment of selected patients with clinically localized prostate cancer
    A D'Amico
    Joint Center for Radiation Therapy, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Endourol 14:367-70. 2000
    ..A real-time three-dimensional magnetic resonance imaging (MRI)-guided implant technique has been designed and implemented. This report summarizes the dosimetry achieved and the acute morbidity in the first patients...
  3. ncbi Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer
    A V D'Amico
    Brigham and Women s Hospital and Dana Farber Cancer Institute, Department of Radiation Therapy, Harvard Medical School, 75 Francis St, L 2 Level, Boston, MA 02115, USA
    JAMA 284:1280-3. 2000
    ....
  4. ncbi Utilizing predictions of early prostate-specific antigen failure to optimize patient selection for adjuvant systemic therapy trials
    A V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 18:3240-6. 2000
    ..This study was performed to estimate 2-year PSA failure rates on the basis of readily available clinical and pathologic factors to identify patients for whom effective adjuvant systemic therapy is needed...
  5. ncbi Pathologic findings and prostate specific antigen outcome after radical prostatectomy for patients diagnosed on the basis of a single microscopic focus of prostate carcinoma with a gleason score </= 7
    A V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer 89:1810-7. 2000
    ..Whether patients who are diagnosed on the basis of a single microscopic focus of prostate carcinoma with a Gleason score </= 7 (micro PC) have potentially life-threatening disease if they are not treated is unknown...
  6. ncbi Clinical utility of percent-positive prostate biopsies in predicting biochemical outcome after radical prostatectomy or external-beam radiation therapy for patients with clinically localized prostate cancer
    A V D'Amico
    Joint Center for Radiation Therapy, Harvard Medical School, Boston, Massachusetts 02215, USA
    Mol Urol 4:171-5;discussion 177. 2000
    ....
  7. ncbi A practical method to achieve prostate gland immobilization and target verification for daily treatment
    A V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02115, USA
    Int J Radiat Oncol Biol Phys 51:1431-6. 2001
    ..A practical method to achieve prostate immobilization and daily target localization for external beam radiation treatment is described...
  8. ncbi The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external-beam radiation therapy for patients with clinically localized prostate cancer
    A V D'Amico
    Joint Center for Radiation Therapy, Harvard Medical School, Boston, MA, USA
    Int J Radiat Oncol Biol Phys 49:679-84. 2001
    ....
  9. ncbi Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer
    A D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital, Boston, Massachusetts 02215, USA
    Urology 58:78-82. 2001
    ..Trials currently underway will examine the efficacy of ADT (4 to 6 months in duration) in patients with clinically localized prostate cancer with >/=1 high-risk features...
  10. ncbi Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer
    A V D'Amico
    Joint Center for Radiation Therapy, Harvard Medical School, Boston, MA 02215, USA
    J Clin Oncol 18:1164-72. 2000
    ..To determine the clinical utility of the percentage of positive prostate biopsies in predicting prostate-specific antigen (PSA) outcome after radical prostatectomy (RP) for men with PSA-detected or clinically palpable prostate cancer...
  11. ncbi Prostate-specific antigen failure despite pathologically organ-confined and margin-negative prostate cancer: the basis for an adjuvant therapy trial
    A V D'Amico
    Joint Center for Radiation Therapy, Harvard Medical School, Boston, MA 02215, USA
    J Clin Oncol 15:1465-9. 1997
    ....
  12. ncbi Calculated prostate cancer volume greater than 4.0 cm3 identifies patients with localized prostate cancer who have a poor prognosis following radical prostatectomy or external-beam radiation therapy
    A V D'Amico
    Joint Center for Radiation Therapy, Harvard Medical School, Boston, MA 02215, USA
    J Clin Oncol 16:3094-100. 1998
    ..This study was performed to validate or refute the prognostic value of the previously defined calculated prostate cancer volume (cV(Ca))...
  13. ncbi Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer
    A V D'Amico
    Joint Center for Radiation Therapy, Harvard Medical School, Boston, Mass 02215, USA
    JAMA 280:969-74. 1998
    ..Interstitial radiation (implant) therapy is used to treat clinically localized adenocarcinoma of the prostate, but how it compares with other treatments is not known...
  14. ncbi Defining the implant treatment volume for patients with low risk prostate cancer: does the anterior base need to be treated?
    A V D'Amico
    Joint Center for Radiation Therapy, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02215, USA
    Int J Radiat Oncol Biol Phys 43:587-90. 1999
    ..The frequency of prostate cancer in this location as a function of the pre-treatment prostate specific antigen (PSA), biopsy Gleason score, and 1992 American Joint Commission on Cancer Staging (AJCC) was determined...
  15. ncbi Optimizing patient selection for dose escalation techniques using the prostate-specific antigen level, biopsy gleason score, and clinical T-stage
    A V D'Amico
    Joint Center for Radiation Therapy, Harvard Medical School, Boston, MA 02215 USA
    Int J Radiat Oncol Biol Phys 45:1227-33. 1999
    ....
  16. ncbi Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer
    A V D'Amico
    Joint Center for Radiation Therapy, Harvard Medical School, and Department of Pathology, Brigham and Women s Hospital, Boston, MA 02215, USA
    J Clin Oncol 17:168-72. 1999
    ....
  17. ncbi Clinical predictors of upgrading to Gleason grade 4 or 5 disease at radical prostatectomy: potential implications for patient selection for radiation and androgen suppression therapy
    A V D'Amico
    Dana Farber Cancer Institute, Department of Radiation Oncology, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02215, USA
    Int J Radiat Oncol Biol Phys 45:841-6. 1999
    ....
  18. ncbi The impact of the biopsy Gleason score on PSA outcome for prostate cancer patients with PSA < or = 10 ng/ml and T1c,2a: implications for patient selection for prostate-only therapy
    A V D'Amico
    Dana Farber Cancer Institute, Department of Radiation Oncology, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02215, USA
    Int J Radiat Oncol Biol Phys 45:847-51. 1999
    ..Specific attention is given to the patient subgroup with biopsy Gleason 3 + 4 vs. 4 + 3...
  19. ncbi Perineural invasion is associated with increased relapse after external beam radiotherapy for men with low-risk prostate cancer and may be a marker for occult, high-grade cancer
    C J Beard
    Department of Radiation Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Boston, MA 02115, USA
    Int J Radiat Oncol Biol Phys 58:19-24. 2004
    ....
  20. ncbi Critical analysis of the ability of the endorectal coil magnetic resonance imaging scan to predict pathologic stage, margin status, and postoperative prostate-specific antigen failure in patients with clinically organ-confined prostate cancer
    A V D'Amico
    Joint Center for Radiation Therapy, Harvard Medical School, Boston, MA, USA
    J Clin Oncol 14:1770-7. 1996
    ....
  21. ncbi Optimizing patient selection for prostate monotherapy
    A K Lee
    Joint Center for Radiation Therapy, Harvard Medical School, 330 Brookline Avenue, 5th Floor, Boston, MA 02215, USA
    Int J Radiat Oncol Biol Phys 49:673-7. 2001
    ....
  22. ncbi Prostate cancer volume adds significantly to prostate-specific antigen in the prediction of early biochemical failure after external beam radiation therapy
    A V D'Amico
    Joint Center for Radiation Therapy, Harvard Medical School, Boston, MA 02747, USA
    Int J Radiat Oncol Biol Phys 35:273-9. 1996
    ..A new clinical pretreatment quantity that closely approximates the true prostate cancer volume is defined...
  23. ncbi Short-course androgen suppression therapy prior to brachytherapy for favorable-risk prostate cancer and the risk of all-cause mortality in men with or without preexisting cardiovascular disease
    J H Hayes
    Dana Farber Cancer Institute, Boston, MA University of Connecticut, Storrs, CT Prostate Cancer Foundation of Chicago, Westmont, IL 21st Century Oncology, Fort Myers, FL Brigham and Women s Hospital, Boston, MA
    J Clin Oncol 27:5066. 2009
    ..The Objective is to determine the effect of short-course androgen suppression therapy (AST) prior to brachytherapy on all cause mortality (ACM), stratified by the presence or absence of preexisting cardiovascular disease (CVD)...
  24. pmc High PSA anxiety and low health literacy skills: drivers of early use of salvage ADT among men with biochemically recurrent prostate cancer after radiotherapy?
    B A Mahal
    Harvard Medical School, Boston
    Ann Oncol 26:1390-5. 2015
    ..We evaluated whether prostate-specific antigen (PSA) anxiety or health literacy are associated with use of early salvage ADT among men with recurrent prostate cancer after radiotherapy...
  25. ncbi A clinical method for real-time dosimetric guidance of transperineal 125I prostate implants using interventional magnetic resonance imaging
    R A Cormack
    Joint Center for Radiation Therapy, Department of Radiation Oncology, Harvard Medical School, Boston, MA 02215, USA
    Int J Radiat Oncol Biol Phys 46:207-14. 2000
    ..The clinical utility of an interventional magnetic resonance (IMR)-guided implant technique with real-time dosimetric feedback is presented...
  26. ncbi Factors associated with a delay in diagnosis of recurrent prostate cancer after radical prostatectomy
    K E Hoffman
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX University of Connecticut, Storrs, CT Dana Farber Cancer Institute Brigham and Women s Hospital, Boston, MA South Carolina College of Pharmacy and the Hollings Cancer Center, Charleston, SC Tulane University, New Orleans, LA Eisai Pharmaceuticals, Woodcliff Lake, NJ
    J Clin Oncol 29:208. 2011
    ..We identified factors associated with delay in diagnosis of recurrent prostate cancer after prostatectomy...
  27. ncbi Comorbidity and treatment regret in men with recurrent prostate cancer
    P L Nguyen
    Dana Farber Cancer Institute Brigham and Women s Hospital, Boston, MA University of Connecticut, Storrs, CT University of North Carolina at Chapel Hill, Chapel Hill, NC Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX Brigham and Women s Hospital, Boston, MA South Carolina College of Pharmacy and the Hollings Cancer Center, Charleston, SC Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH Tulane University, New Orleans, LA Eisai Pharmaceuticals, Woodcliff Lake, NJ
    J Clin Oncol 29:187. 2011
    ..187 Background: To determine whether concurrent comorbidity is associated with treatment regret among men with PSA recurrence following primary therapy for prostate cancer...
  28. ncbi Optimizing target coverage by dosimetric feedback during prostate brachytherapy
    R A Cormack
    Department of Radiation Oncology, Harvard Medical School, Boston, MA, USA
    Int J Radiat Oncol Biol Phys 48:1245-9. 2000
    ..The significance of needle misplacement and the clinical utility of dosimetric feedback were analyzed in the setting of interventional magnetic resonance (IMR) guided prostate brachytherapy...
  29. ncbi Predictors of prostate cancer-specific mortality in elderly men with intermediate-risk prostate cancer treated with radiation therapy
    A Nanda
    Harvard Radiation Oncology Program, Boston, MA University of Connecticut, Storrs, CT Prostate Cancer Foundation of Chicago, Westmont, IL 21st Century Oncology, Fort Myers, FL Brigham and Women s Hospital, Boston, MA
    J Clin Oncol 27:9543. 2009
    ....
  30. ncbi Race and survival following brachytherapy-based treatment for men with localized or locally advanced adenocarcinoma of the prostate
    K M Winkfield
    Harvard Radiation Oncology Program, Boston, MA University of Connecticut, Storrs, CT 21st Century Oncology, Fort Myers, FL Brigham and Women s Hospital, Boston, MA
    J Clin Oncol 27:5068. 2009
    ..5068 Purpose: We investigated whether race was associated with risk of death following brachytherapy-based treatment for localized prostate cancer...
  31. doi Duration of the anti-androgen in men undergoing 6 months of an LHRH agonist and radiation therapy for unfavorable-risk prostate cancer and the risk of death
    N N Sanford
    Department of Radiation Oncology, Brigham and Women s Hospital, Boston, MA, USA
    Prostate Cancer Prostatic Dis . 2016
    ....
  32. ncbi A software system for interventional magnetic resonance image-guided prostate brachytherapy
    H M Kooy
    Joint Center for Radiation Therapy, Department of Radiation Oncology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Comput Aided Surg 5:401-13. 2000
    ..The system permits the surgeon and patient to complete all phases of treatment in one setting...
  33. ncbi Tamsulosin palliates radiation-induced urethritis in patients with prostate cancer: results of a pilot study
    R G Prosnitz
    Joint Center for Radiation Therapy, Harvard Medical School, Boston, MA 02215, USA
    Int J Radiat Oncol Biol Phys 45:563-6. 1999
    ..Potential predictors of response to Flomax were evaluated...
  34. ncbi Biopsy Gleason score and the duration of testosterone suppression among men treated with external beam radiation and six months of combined androgen blockade
    N E Martin
    Dana Farber Cancer Institute Brigham and Women s Hospital, Boston, MA University of Connecticut, Storrs, CT Dana Farber Cancer Institute, Boston, MA
    J Clin Oncol 29:191. 2011
    ..We investigated whether the biopsy Gleason score (BGS) was associated with duration of TS...
  35. doi The impact of comorbidity and PSA doubling time on the risk of death in men experiencing PSA failure following radiation therapy with or with androgen deprivation therapy for unfavorable-risk prostate cancer
    S A Patel
    Harvard Radiation Oncology Program, Harvard Medical School, Boston, MA, USA
    Prostate Cancer Prostatic Dis . 2017
    ..We investigated the impact that PSA doubling time (DT) and comorbidity had on the risk of all-cause mortality (ACM), prostate cancer-specific mortality (PCSM) and other-cause mortality (OCM) following PSA failure...
  36. ncbi Towards enzyme activated antiprostatic agents
    G B Jones
    Department of Chemistry, Northeastern University, Boston, MA 02115, USA
    Bioorg Med Chem Lett 10:1987-9. 2000
    ..The prodrug system undergoes activation with PSA or alpha-chymotrypsin, and shows selective cytotoxicity in a PSA secreting cell line...
  37. ncbi Prostate cancer screening practice among men age 75 and older: Results from a national survey
    K E Hoffman
    Harvard Radiation Oncology Program, Boston, MA Dana Farber Cancer Institute Brigham and Women s Hospital, Boston, MA
    J Clin Oncol 27:e16034. 2009
    ..This study evaluated the use of prostate specific antigen (PSA) screening among men age 75 and older prior to this declaration...
  38. ncbi Diabetes mellitus, race, and the odds of high-grade prostate cancer in men diagnosed with prostate cancer in the United States
    T Mitin
    Brigham and Women s Hospital, Boston, MA University of Connecticut, Storrs, CT Prostate Cancer Foundation of Chicago, Westmont, IL 21st Century Oncology, Fort Myers, FL Dana Farber Cancer Institute Brigham and Women s Hospital, Boston, MA
    J Clin Oncol 29:180. 2011
    ..We evaluated whether there is an independent association between DM and the risk of high-grade PCa in men diagnosed with PCa, adjusting for the known predictors of high-grade PCa including AA race...
  39. ncbi The association between overexpression of skp2 and the risk of recurrence following prostatectomy
    P L Nguyen
    Harvard Radiation Oncology Program, Boston, MA Jdxpath, Collegeville, PA Dana Farber Cancer Institute, Boston, MA Brigham and Women s Hospital, Boston, MA University of Pennsylvania School of Medicine, Philadelphia, PA New York University Medical Center, New York, NY WakeMed Health, Raleigh, NC
    J Clin Oncol 26:11052. 2008
    ..We sought to determine whether Skp2 overexpression is associated with p27 suppression and an increased risk of recurrence among men with prostate cancer treated with prostatectomy...
  40. pmc A refined risk stratification scheme for clinical stage 1 NSGCT based on evaluation of both embryonal predominance and lymphovascular invasion
    C A Lago-Hernandez
    Harvard Medical School, Boston Department of Medical Oncology Genitourinary Division, Dana Farber Cancer Institute, Boston
    Ann Oncol 26:1396-401. 2015
    ....
  41. pmc The association between race and treatment regret among men with recurrent prostate cancer
    B A Mahal
    Harvard Medical School, Boston, MA, USA
    Prostate Cancer Prostatic Dis 18:38-42. 2015
    ..To examine the impact of race on treatment regret among men with recurrent prostate cancer after surgery or radiation...